Exenatide
- Generic Name
- Exenatide
- Brand Names
- Bydureon, Byetta
- Drug Type
- Biotech
- CAS Number
- 141758-74-9
- Unique Ingredient Identifier
- 9P1872D4OL
- Background
Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations. Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available.
- Indication
Exenatide is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. An extended-release formulation is available which is indicated in patients ≥10 years old, while the immediate-acting formulation is approved only for adult patients.
- Associated Conditions
- Type 2 Diabetes Mellitus
An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 137
- Registration Number
- NCT00135330
- Locations
- 🇺🇸
Research Site, Spokane, Washington, United States
Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes
- First Posted Date
- 2005-05-24
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 456
- Registration Number
- NCT00111540
- Locations
- 🇺🇸
Research Site, Spokane, Washington, United States
Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes
- First Posted Date
- 2005-02-18
- Last Posted Date
- 2015-02-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 45
- Registration Number
- NCT00103935
- Locations
- 🇺🇸
Research Site, Olympia, Washington, United States
Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin
- First Posted Date
- 2004-12-13
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 182
- Registration Number
- NCT00099320
- Locations
- 🇪🇸
Research Site, Zaragoza, Spain
Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents
- First Posted Date
- 2004-12-13
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 49
- Registration Number
- NCT00099333
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2004-11-25
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 69
- Registration Number
- NCT00097500
- Locations
- 🇸🇪
Research Site, Goteborg, Sweden
Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Placebo 0.04 mL once dailyDrug: Placebo 0.04 mL twice dailyDrug: Placebo 0.08 mL once dailyDrug: B - Exenatide 10 mcg twice dailyDrug: C - Exenatide 10 mcg once daily
- First Posted Date
- 2004-06-22
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 99
- Registration Number
- NCT00085969
- Locations
- 🇺🇸
Mercury Street Medical Group, Butte, Montana, United States
🇺🇸MedStar Research Institute, Washington, District of Columbia, United States
🇺🇸Metrolina Medical Research, Charlotte, North Carolina, United States
Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2004-05-11
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 551
- Registration Number
- NCT00082381
- Locations
- 🇺🇸
Internal Medicine Associates Department of Research, Fort Myers, Florida, United States
🇳🇱Diabetes Centrum Bilthoven, Bilthoven, Netherlands
🇳🇱Medisch Centrum, Westeinde, Netherlands
Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2004-05-10
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 505
- Registration Number
- NCT00082407
- Locations
- 🇵🇹
Hospital Pedro Hispano, Matosinhos, Portugal
🇭🇷Clinical Hospital Osijek, Osijek, Croatia
🇭🇷Klinica bolnica Dubrava, Zagreb, Croatia
Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination
- First Posted Date
- 2002-09-05
- Last Posted Date
- 2015-02-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 155
- Registration Number
- NCT00044668
- Locations
- 🇭🇺
Uzsoki Street Municipal Hospital, Budapest, Hungary
🇭🇺Peterfy Teaching Hospital, Budapest, Hungary
🇭🇺Diagnostic Units Hungary Kft., Budapest, Hungary
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.